5.06
-0.07(-1.36%)
Currency In USD
| Previous Close | 5.13 |
| Open | 5.21 |
| Day High | 5.35 |
| Day Low | 5.05 |
| 52-Week High | 67.5 |
| 52-Week Low | 4.11 |
| Volume | 46,647 |
| Average Volume | 145,468 |
| Market Cap | 16.15M |
| PE | -0.21 |
| EPS | -24.28 |
| Moving Average 50 Days | 4.87 |
| Moving Average 200 Days | 9.27 |
| Change | -0.07 |
If you invested $1000 in Cellectar Biosciences, Inc. (CLRB) 10 years ago, it would be worth $0.06 as of September 18, 2025 at a share price of $5.06. Whereas If you bought $1000 worth of Cellectar Biosciences, Inc. (CLRB) shares 5 years ago, it would be worth $13.94 as of September 18, 2025 at a share price of $5.06.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
GlobeNewswire Inc.
Sep 11, 2025 12:05 PM GMT
Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid TumorsFLORHAM PARK, N.J. and GARCHING, Germany and MUNICH, Germany, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB, “Cel
Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit
GlobeNewswire Inc.
Sep 09, 2025 12:05 PM GMT
Highlighting Continued Progress with EMA Regarding a Potential Conditional Marketing Authorization Submission for Iopofosine I 131 to Treat Waldenstrom Macroglobulinemia (WM) in the EU; Decision on Track for Late 3Q25/Early 4Q25 Intention to Pursue a
Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September
GlobeNewswire Inc.
Sep 05, 2025 12:45 PM GMT
FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for the treatment of cancer, today announced that J